Denmark · Delayed Price · Currency is DKK Coloplast Statistics
Total Valuation
Coloplast has a market cap or net worth of DKK 132.74 billion. The enterprise value is 154.43 billion.
| Market Cap | 132.74B |
| Enterprise Value | 154.43B |
Important Dates
The last earnings date was Tuesday, November 4, 2025.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | Dec 5, 2025 |
Share Statistics
Coloplast has 225.37 million shares outstanding. The number of shares has increased by 0.22% in one year.
| Current Share Class | 207.37M |
| Shares Outstanding | 225.37M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 5.32% |
| Owned by Institutions (%) | 21.63% |
| Float | 143.59M |
Valuation Ratios
The trailing PE ratio is 36.52 and the forward PE ratio is 22.93. Coloplast's PEG ratio is 1.46.
| PE Ratio | 36.52 |
| Forward PE | 22.93 |
| PS Ratio | 4.76 |
| PB Ratio | 8.23 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 24.86 |
| P/OCF Ratio | 19.98 |
| PEG Ratio | 1.46 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.32, with an EV/FCF ratio of 28.93.
| EV / Earnings | 42.47 |
| EV / Sales | 5.54 |
| EV / EBITDA | 17.32 |
| EV / EBIT | 20.00 |
| EV / FCF | 28.93 |
Financial Position
The company has a current ratio of 1.61, with a Debt / Equity ratio of 1.40.
| Current Ratio | 1.61 |
| Quick Ratio | 0.94 |
| Debt / Equity | 1.40 |
| Debt / EBITDA | 2.54 |
| Debt / FCF | 4.24 |
| Interest Coverage | 10.25 |
Financial Efficiency
Return on equity (ROE) is 21.35% and return on invested capital (ROIC) is 12.17%.
| Return on Equity (ROE) | 21.35% |
| Return on Assets (ROA) | 10.01% |
| Return on Invested Capital (ROIC) | 12.17% |
| Return on Capital Employed (ROCE) | 18.44% |
| Revenue Per Employee | 1.66M |
| Profits Per Employee | 217,152 |
| Employee Count | 16,744 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.35 |
Taxes
In the past 12 months, Coloplast has paid 2.52 billion in taxes.
| Income Tax | 2.52B |
| Effective Tax Rate | 40.95% |
Stock Price Statistics
The stock price has decreased by -33.04% in the last 52 weeks. The beta is 0.62, so Coloplast's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -33.04% |
| 50-Day Moving Average | 589.36 |
| 200-Day Moving Average | 652.32 |
| Relative Strength Index (RSI) | 45.98 |
| Average Volume (20 Days) | 252,613 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Coloplast had revenue of DKK 27.87 billion and earned 3.64 billion in profits. Earnings per share was 16.13.
| Revenue | 27.87B |
| Gross Profit | 18.95B |
| Operating Income | 7.72B |
| Pretax Income | 6.16B |
| Net Income | 3.64B |
| EBITDA | 8.63B |
| EBIT | 7.72B |
| Earnings Per Share (EPS) | 16.13 |
Balance Sheet
The company has 947.00 million in cash and 22.64 billion in debt, giving a net cash position of -21.69 billion or -96.25 per share.
| Cash & Cash Equivalents | 947.00M |
| Total Debt | 22.64B |
| Net Cash | -21.69B |
| Net Cash Per Share | -96.25 |
| Equity (Book Value) | 16.12B |
| Book Value Per Share | 71.54 |
| Working Capital | 3.95B |
Cash Flow
In the last 12 months, operating cash flow was 6.65 billion and capital expenditures -1.31 billion, giving a free cash flow of 5.34 billion.
| Operating Cash Flow | 6.65B |
| Capital Expenditures | -1.31B |
| Free Cash Flow | 5.34B |
| FCF Per Share | 23.69 |
Margins
Gross margin is 67.97%, with operating and profit margins of 27.70% and 13.04%.
| Gross Margin | 67.97% |
| Operating Margin | 27.70% |
| Pretax Margin | 22.09% |
| Profit Margin | 13.04% |
| EBITDA Margin | 30.96% |
| EBIT Margin | 27.70% |
| FCF Margin | 19.15% |
Dividends & Yields
This stock pays an annual dividend of 23.00, which amounts to a dividend yield of 3.90%.
| Dividend Per Share | 23.00 |
| Dividend Yield | 3.90% |
| Dividend Growth (YoY) | 4.55% |
| Years of Dividend Growth | 16 |
| Payout Ratio | 136.36% |
| Buyback Yield | -0.22% |
| Shareholder Yield | 3.60% |
| Earnings Yield | 2.74% |
| FCF Yield | 4.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 19, 2012. It was a forward split with a ratio of 5.
| Last Split Date | Dec 19, 2012 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Coloplast has an Altman Z-Score of 4.76 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.76 |
| Piotroski F-Score | 7 |